AHA 2025 Clinical Insights: Advancing Cardiology Care

Episodes 1-15 of 15

• 

  RestartResume

  Sotagliflozin in HFpEF Without Diabetes: Inside the SOTA-P-CARDIA Trial from AHA 2025

  RestartResume

  Sotagliflozin in HFpEF Without Diabetes: Inside the SOTA-P-CARDIA Trial from AHA 2025

  AHA 2025 Clinical Insights: Advancing Cardiology Care

  Sotagliflozin in HFpEF Without Diabetes: Inside the SOTA-P-CARDIA Trial from AHA 2025

  • 

    

    Juan Badimon, PhD, FAHA

• 

  RestartResume

  Highlights of the Latest Hypertension Guidelines

  RestartResume

  Highlights of the Latest Hypertension Guidelines

  AHA 2025 Clinical Insights: Advancing Cardiology Care

  Highlights of the Latest Hypertension Guidelines

  • 

    

    Clyde W. Yancy, MD

• 

  RestartResume

  Clinical Perspective on New Therapies in Resistant Hypertension

  RestartResume

  Clinical Perspective on New Therapies in Resistant Hypertension

  AHA 2025 Clinical Insights: Advancing Cardiology Care

  Clinical Perspective on New Therapies in Resistant Hypertension

  • 

    

    Clyde W. Yancy, MD

• 

  RestartResume

  Precision Medicine in Obstructive HCM Care: The Promise of Cardiac Myosin Inhibitors

  RestartResume

  Precision Medicine in Obstructive HCM Care: The Promise of Cardiac Myosin Inhibitors

  Hypertrophic Cardiomyopathy

  Precision Medicine in Obstructive HCM Care: The Promise of Cardiac Myosin Inhibitors

  • 

    

    Ahmad Masri, MD, MS

• 

  RestartResume

  The Lp(a)-Lowering Landscape: Navigating Current and Future Therapeutic Options

  RestartResume

  The Lp(a)-Lowering Landscape: Navigating Current and Future Therapeutic Options

  AHA 2025 Clinical Insights: Advancing Cardiology Care

  The Lp(a)-Lowering Landscape: Navigating Current and Future Therapeutic Options

  • 

    

    Erin Michos

• 

  RestartResume

  DARE AF Trial: Dapagliflozin to Reduce AF Burden After Catheter Ablation in Patients Without Diabetes or Heart Failure

  RestartResume

  DARE AF Trial: Dapagliflozin to Reduce AF Burden After Catheter Ablation in Patients Without Diabetes or Heart Failure

  Atrial Fibrillation

  DARE AF Trial: Dapagliflozin to Reduce AF Burden After Catheter Ablation in Patients Without Diabetes or Heart Failure

  • 

    

    Clyde W. Yancy, MD

• 

  RestartResume

  DECAF Trial: Does Eliminating Coffee Reduce Atrial Fibrillation Recurrence in Symptomatic Patients?

  RestartResume

  DECAF Trial: Does Eliminating Coffee Reduce Atrial Fibrillation Recurrence in Symptomatic Patients?

  Atrial Fibrillation

  DECAF Trial: Does Eliminating Coffee Reduce Atrial Fibrillation Recurrence in Symptomatic Patients?

  • 

    

    Christopher Wong

• 

  RestartResume

  POLY HF Trial: A Polypill Strategy for Heart Failure With Reduced Ejection Fraction (HFrEF)

  RestartResume

  POLY HF Trial: A Polypill Strategy for Heart Failure With Reduced Ejection Fraction (HFrEF)

  Heart Failure

  POLY HF Trial: A Polypill Strategy for Heart Failure With Reduced Ejection Fraction (HFrEF)

  • 

    

    Ambarish Pandey, MD

• 

  RestartResume

  The LDL-C-Lowering Landscape: Navigating Current and Future Therapeutic Options

  RestartResume

  The LDL-C-Lowering Landscape: Navigating Current and Future Therapeutic Options

  AHA 2025 Clinical Insights: Advancing Cardiology Care

  The LDL-C-Lowering Landscape: Navigating Current and Future Therapeutic Options

  • 

    

    Prof. Kausik Ray

• 

  RestartResume

  ADAPT AF-DES: Antithrombotic Strategies Beyond 12 Months for Patients With AF Treated With Drug-Eluting-Stents

  RestartResume

  ADAPT AF-DES: Antithrombotic Strategies Beyond 12 Months for Patients With AF Treated With Drug-Eluting-Stents

  Atrial Fibrillation

  ADAPT AF-DES: Antithrombotic Strategies Beyond 12 Months for Patients With AF Treated With Drug-Eluting-Stents

  • 

    

    Jung-Sun Kim, MD, PhD

• 

  RestartResume

  OCEAN Trial at AHA 2025: Anticoagulation After AF Ablation in High-Risk Patients

  RestartResume

  OCEAN Trial at AHA 2025: Anticoagulation After AF Ablation in High-Risk Patients

  Atrial Fibrillation

  OCEAN Trial at AHA 2025: Anticoagulation After AF Ablation in High-Risk Patients

  • 

    

    Atul Verma, MD

• 

  RestartResume

  Primary Results of the VESALIUS-CV Trial: Evolocumab in Patients at High Cardiovascular Risk Without Prior MI or Stroke

  RestartResume

  Primary Results of the VESALIUS-CV Trial: Evolocumab in Patients at High Cardiovascular Risk Without Prior MI or Stroke

  Hyperlipidemia

  Primary Results of the VESALIUS-CV Trial: Evolocumab in Patients at High Cardiovascular Risk Without Prior MI or Stroke

  • 

    

    Erin Bohula, MD, DPhil

• 

  RestartResume

  Real-World Impact of Evolocumab on MACE Reduction in ASCVD

  RestartResume

  Real-World Impact of Evolocumab on MACE Reduction in ASCVD

  Hyperlipidemia

  Real-World Impact of Evolocumab on MACE Reduction in ASCVD

  • 

    

    Nihar Desai, MD

• 

  RestartResume

  Global Burden of Stroke and Myocardial Infarction in Patients at High Risk of First MACE: Insights From the VESALIUS-REAL Study

  RestartResume

  Global Burden of Stroke and Myocardial Infarction in Patients at High Risk of First MACE: Insights From the VESALIUS-REAL Study

  Hyperlipidemia

  Global Burden of Stroke and Myocardial Infarction in Patients at High Risk of First MACE: Insights From the VESALIUS-REAL Study

  • 

    

    Matthew Jay Budoff, MD

• 

  RestartResume

  Evolocumab in Patients at High Cardiovascular Risk Without Prior MI or Stroke: Primary Results of the VESALIUS-CV Trial 

  RestartResume

  Evolocumab in Patients at High Cardiovascular Risk Without Prior MI or Stroke: Primary Results of the VESALIUS-CV Trial 

  Hyperlipidemia

  Evolocumab in Patients at High Cardiovascular Risk Without Prior MI or Stroke: Primary Results of the VESALIUS-CV Trial 

  • 

    

    Lawrence Leiter